9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2009 Transient dephosphorylation of p53 serine 376 as an early response to ionizing radiation. Radiat Res,171(6),725-34.
2. 2009 Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix Am J Clin Oncol,32(4),411-6.
3. 2009 Differential gene expression in primary human skin keratinocytes and fibroblasts in response to ionizing radiation. Radiat Res,172(1),82-95.
4. 2009 Survival and recurrence in nonmycosis fungoides primary cutaneous lymphoma. Cancer J,15(1),87-92.
5. 2009 Practice Patterns of Radiotherapy in Endometrial Cancer Among Member Groups of the Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer,19(3),395-9.
6. 2009 Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study Int J Gynecol Cancer,19(1),163-7.
7. 2009 Patterns of Care for Radiotherapy in Vulvar Cancer: A Gynecologic Cancer Intergroup (GCIG) Study. Int J Gynecol Cancer,19(1),163-7.
8. 2009 Gynecologic Cancer Intergroup proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol,143,69-74
9. 2009 Current challenges in clinical management of endometrial cancer Adv Drug Deliv Rev,61,883-889.
10. 2009 Does the Entire Uterus Need to Be Treated in Cancer of the Cervix? Role of Adaptive Brachytherapy. Int J Radiat Oncol Biol Phys.(Epub ahead of print).
11. 2009 Differential gene expression in primary human skin keratinocytes and fibroblasts in response to ionizing radiation Radiat Res,172,82-95.
12. 2009 Transient Dephosphorylation of p53 Serine 376 as an Early Response to Ionizing Radiation Radiat Res,171,725-34.
13. 2008 The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol,88(2),227-32.
14. 2008 Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol,111(6),1394-402
15. 2008 Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128 Gynecol Oncol,109(2),275-9.
16. 2008 Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis Int J Gynecol Cancer,18(2),255-61
17. 2008 Consensus Guidelines for Deliniation of Clinical Target Volume for Intesnsity-=Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer Int J Radiat Oncol Biol Phys,71(2),428-34.
18. 2008 Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128. Clin Cancer Res,15(12),4199-4206.
19. 2008 Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. Int J Radiat Oncol Biol Phys,70(1),111-7.
20. 2008 Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw,6(8),766-94.
21. 2007 A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys,67(1),104-9.
22. 2007 Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer,110(9),2092-100.
23. 2007 Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128 Int J Radiat Oncol Biol Phys,69(1),111-7.
24. 2007 An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer Brachytherapy,6(3),201-6.
25. 2007 Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG) Int J Radiat Oncol Biol Phys,68(2),485-90
26. 2007 The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Am J Clin Oncol,30(2),156-62.
27. 2007 Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: Results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys,68(4),1081-7.
28. 2007 Clinical trials in gynecological cancer. Int J Gynecol Cancer,17(3),547-56
29. 2007 Cause specific survival following surgery in malignant phyllodes tumor of the female breast. Am J Hematol Oncol,6(5),289-92.
30. 2007 Gynecologic Cancer Intergroup. Clinical trials in Gynecological Cancer Int J Gynecol Cancer,17(3),547-56.
31. 2006 Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer,107(10),2392-400.
32. 2006 Ovarian cancer. Clinical practice guidelines in oncology J Natl Compr Canc Netw,4(9),912-39.
33. 2006 Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer Int J Radiat Oncol Biol Phys,65(5),1411-5
34. 2006 The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer,107(1),108-15.
35. 2006 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol,24(16),2437-43.
36. 2006 The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol,29(2),189-95.
37. 2006 Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA,295(4),389-97.
38. 2006 Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res,12(1),250-6.
39. 2006 Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer,107(9),2127-33.
40. 2006 Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: a multi-institutional analysis of 608 women Gynecol Oncol,103(2),661-6.
41. 2005 Feasibility of RNA collection for micro-array gene expression analysis in the treatment of cervical carcinoma: a scientific correlate of RTOG C-0128. Gynecol Oncol,97(2),607-11.
42. 2005 Intracranial extramedullary hematopoiesis: brief review of response to radiation therapy Am J Hematol,78(2),151-2.
43. 2005 Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol,99(2),415-21
44. 2005 Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium? Gynecol Oncol,99(3),730-5.
45. 2004 Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy Int J Radiat Oncol Biol Phys,58(4),1034-40.
46. 2004 Time interval to the development of breast carcinoma after treatment for Hodgkin disease Cancer,101(6),1275-82.
47. 2004 Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol,93(1),209-14.
48. 2004 Does radiotherapy around the time of pregnancy for Hodgkin's disease modify the risk of breast cancer? Int J Radiat Oncol Biol Phys,58(5),1474-9.
49. 2004 Rapid involution and mobility of carcinoma of the cervix Int J Radiat Oncol Biol Phys,58(2),625-30.
50. 2004 Is simulation necessary for each high-dose-rate tandem and ovoid insertion in carcinoma of the cervix? Brachytherapy,3(3),120-4
51. 2004 Ovarian Cancer: Clinical Practice Guidelines J Natl Compr Canc Netw,2(6),526-547.
52. 2004 Electron arc radiotherapy after breast reconstruction: the results of the University of Utah experience Am J Clin Oncol,27(6),555-564
53. 2003 Diminished survival in patients with inner versus outer quadrant breast cancers. J Clin Oncol,21(3),467-72.
54. 2003 Electron arc irradiation of the postmastectomy chest wall in locally recurrent and metastatic breast cancer. Am J Clin Oncol,26(3),241-6.
55. 2003 Facilitation of radiotherapeutic error by computerized record and verify systems. Int J Radiat Oncol Biol Phys,56(1),50-7.
56. 2003 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys,56(4),922-8
57. 2002 Forward planning using multileaf collimation as a replacement for patient tissue compensation. Med Dosim,27(4),245-9
58. 2002 Long-term follow-up of RTOG 88-05: Twice daily external irradiation with brachytherapy for carcinoma of the cervix Int J Radiat Oncol Biol Phys,54(1),51-7.
59. 2002 Dose calculation errors due to inaccurate representation of heterogeneity correction obtained from computerized tomography Med Dosim,27(4),275-8.
60. 2001 Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy Int J Radiat Oncol Biol Phys,49(5),1213-7.
61. 2001 Electron arc irradiation of the postmastectomy chest wall with CT treatment planning: 20-year experience. Int J Radiat Oncol Biol Phys,51(4),994-1001.
62. 2001 Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol,24(5),443-6
63. 2001 Intensity-modulated radiosurgery/radiotherapy using a micromultileaf collimator. Med Dosim,26(2),143-50.
64. 2001 Gynecology Cancer Working Group Int J Radiat Oncol Biol Phys,51(3 suppl 2),58-9.
65. 2000 Application of enhanced dynamic wedge to stereotactic radiotherapy Med Dosim,25(2),61-9
66. 2000 Effects of modifying topoisomerase II levels on cellular recovery from radiation damage. Radiat Res,154(4),461-6.
67. 2000 Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations J Clin Oncol,18(19),3360-9.
68. 2000 Comparison of interpolated vs. calculated micromultileaf settings in dynamic conformal arc treatment Med Dosim,25(1),17-21.
69. 1999 Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol,30(4),384-91.
70. 1999 Dosimetric comparison between 192-Ir and 125-I for low dose rate interstitial implants of the base of tongue. J Brachyther Int,15(1),27-35.
71. 1998 Pathobiologic characteristics of hereditary breast cancer. Hum Pathol,29(10),1140-4.
72. 1998 Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol,47(2),129-36
73. 1997 Dose to the contralateral breast: a comparison of two techniques using the enhanced dynamic wedge versus a standard wedge Med Dosim,22(3),185-91.
74. 1997 Electron arc irradiation of the postmastectomy chest wall: clinical results Radiother Oncol,42(1),17-24
75. 1997 Dosimetric parameters of enhanced dynamic wedge for treatment planning and verification. Med Dosim,22(3),177-83
76. 1995 Iododeoxyuridine Radiosensitization of Human Glioblastoma Cells Exposed to Acute and Chronic Gamma Irradiation. Cancer J Sci Am,1(2),151
77. 1992 The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells Biochim Biophys Acta,1117(3),321-5
78. 1992 Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity Blood,80(1),277-85
79. 1992 Antiviral effects of photosensitizing merocyanine dyes: implications for transfusion and bone marrow transplantation Semin Hematol,29(2),79-87
80. 1992 The role of serum and serum components in the merocyanine 540-sensitized photoinactivation of K562 leukemia cells Biochim Biophys Acta,1117(3),321-5.
81. 1992 Merocyanine-sensitized photoinactivation of enveloped viruses Blood Cells,18(1),117-27.
82. 1992 Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity. Blood,80(1),277-85
83. 1991 Cholesterol content but not plasma membrane fluidity influences the susceptibility of L1210 leukemia cells to merocyanine 540-sensitized irradiation. Photochem Photobiol,54(5),717-23.
84. 1991 Plasma membrane properties regulating the sensitivity of leukemia, lymphoma, and solid tumor cells to merocyanine 540-sensitized photoirradiation. Exp Hematol,19(8),785-8.
85. 1991 Modulation by thiols of the merocyanine 540-sensitized photolysis of leukemia cells, red cells, and herpes simplex virus type 1 Photochem Photobiol,53(1),85-92.
86. 1990 Merocyanine 540-sensitized photoinactivation of soluble and membrane-bound enzymes in L1210 leukemia cells. Cancer Res,50(24),7765-9
87. 1990 Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products. J Lab Clin Med,116(4),439-47.
88. 1990 Merocyanine 540-sensitized photoinactivation of leukemia cells: role of oxygen and effects on plasma membrane integrity and mitochondrial respiration. Exp Hematol,18(1),23-6.
89. 1986 Nicotine-induced tolerance and receptor changes in four mouse strains. J Pharmacol Exp Ther,237(3),809-19.
90. 1986 Genetic influences on GABA-related seizures Pharmacol Biochem Behav,24(3),665-72.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.